| abstract |
Disclosed is a drug for the treatment of hyperbilirubinemia or symptoms thereof in infants. A stannsoporphine, which is a type of metalloporphyrin, in which the metallo moiety is tin, has no exclusion factor, the total bilirubin level of at least one baseline exceeds a predetermined threshold, and at least one risk factor is present Injecting a therapeutic amount of stannsoporfin to an infant with hyperbilirubinemia present, with a threshold of 1-3 mg for phototherapy according to the 2004 AAP (American Pediatric Academy) nomogram corresponding to infant age / DL, wherein the therapeutic amount of stannsoporfin is 0.75-5 mg / kg based on the weight of the infant. The infant has a gestation period of 35 to 43 weeks, and is administered at a time selected from within 6 hours, within 12 hours, within 24 hours or within 48 hours after administration of a therapeutic amount of stannsoporfin, Drug. [Selection figure] None |